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OUT is a clinical syndrome resulting from the dep-
osition of urate (monosodium urate monohydrate)
crystals. The crystals may be deposited in a joint, lead-
ing to an acute inﬂammatory response, or in soft tissues,
such as cartilage, causing no inﬂammation. Most cases
of gout are characterized by the sudden onset of severe
acute monarticular arthritis in a peripheral joint in the
leg. The arthritis remits completely and then recurs with
increasing frequency. After approximately 10 years of
recurrent gouty arthritis, tophi develop in cartilage, ten-
dons, and bursae in some patients.
Established criteria for the diagnosis of gout include
the presence of urate crystals in joint ﬂuid, the develop-
ment of a tophus, or the presence of the characteristic
clinical pattern described above.
 
1
 
 Occasionally, a pa-
tient may have a more chronic or less severe arthritis
affecting more than one joint at a time, in which case
the diagnosis depends entirely on the detection of urate
crystals. In some patients, urate crystals have been de-
tected in joints in which there has been no inﬂamma-
tion,
 
2,3
 
 but most of these patients have had at least one
previous attack of gout. There are also reports of tophi
developing without prior arthritis,
 
4
 
 chieﬂy in elderly
women with renal insufﬁciency who were taking diuret-
ic or nonsteroidal antiinﬂammatory drugs.
 
5
 
Although hyperuricemia is not a requirement for the
diagnosis of gout
 
1
 
 and its presence in a patient with ar-
thritis does not necessarily establish that diagnosis, the
risk of gout increases with the degree and duration of
hyperuricemia (Table 1). However, among patients
with serum urate concentrations of 9.0 mg per deciliter
(540 
 
m
 
mol per liter), the incidence of acute gout is only
about 5 percent per year.
 
6,7
 
 Hyperuricemia may occur
in a wide variety of conditions, genetic or acquired,
metabolic or renal. Asymptomatic hyperuricemia does
not have any adverse effects before the development of
gout.
 
6-8
 
 Drug treatment is therefore not required, al-
though it is prudent to determine the causes of the hy-
peruricemia and correct them, if possible.
For simplicity and uniformity, the term “urate” is
used here instead of the more common term, “uric
acid,” because, at physiologic pH, 99 percent of the mol-
ecules are in the form of urate. Only in parts of the uri-
nary tract where the pH is less than 5.7 are most of the
molecules in the form of uric acid, which because of its
poorer solubility may be present as uric acid crystals.
 
T
 
REATMENT
 
 
 
OF
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CUTE
 
 G
 
OUTY
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RTHRITIS
 
Three treatments are available for patients with
acute gouty arthritis. Colchicine is less favored now
than in the past, because its onset of action is slow and
it invariably causes diarrhea.
 
9
 
 Nonsteroidal antiinﬂam-
matory drugs, which are currently favored, are rapidly
effective but may have serious side effects. Corticoster-
oids, administered either intraarticularly or parenteral-
ly, are used increasingly in patients with monarticular
gout,
 
10-13
 
 especially if oral drug therapy is not feasible.
Therapy that might alter serum urate concentrations
should not be initiated or changed as long as any gouty
joint inﬂammation persists, because such treatment
may delay the recovery. The choice of a drug depends
on an assessment of its efﬁcacy as compared with its
toxic effects in the treatment of a particular attack in
a particular patient. However, nonsteroidal antiinﬂam-
matory drugs are generally favored unless the risk of
side effects is judged to be too high.
 
Colchicine
 
The beneﬁt of colchicine in treating gout is related
principally to its ability to inhibit phagocytosis of urate
crystals by neutrophils (Table 2). Colchicine forms a
tubulin–colchicine dimer that caps the assembly end
of the microtubules, interfering with the transport of
phagocytosed material to lysosomes. Colchicine also
blocks the release of chemotactic factor,
 
14
 
 reduces the
mobility and adhesion of polymorphonuclear leuko-
cytes, and inhibits tyrosine phosphorylation and the
generation of leukotriene B
 
4
 
.
 
15 
 
The effective dose of colchicine in patients with acute
gout is close to that which causes gastrointestinal symp-
toms. The drug is usually administered orally in a dose
of 1 mg initially, followed by 0.5 mg every two hours
until abdominal discomfort or diarrhea develops or a
total dose of 8 mg has been administered. Most patients
have some pain relief by 18 hours and diarrhea by 24
hours; joint inﬂammation subsides gradually in 75 to 80
percent of patients within 48 hours.
 
9
 
 Except in patients
who have renal or hepatic dysfunction or are elderly
and frail, colchicine given in this way is safe, although
it entails some discomfort for the patient.
Colchicine may be given intravenously if oral admin-
istration is not possible or if there is a need to avoid
gastrointestinal side effects. The risk of systemic toxic
effects (marrow suppression and injury of renal, hepat-
ic, and central nervous system cells) is much greater
with intravenous therapy than with oral therapy. Safe
intravenous therapy depends on the following guide-
lines.
 
38,39
 
 An initial dose of 2 mg should be administered
through an established intravenous catheter (to mini-
mize the risk of extravasation); two additional doses of
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1 mg each may be given at six-hour intervals, but the
total dose should never exceed 4 mg. The doses should
be reduced by at least 50 percent in patients with he-
patic or renal disease and in elderly patients. The intra-
venous preparation of colchicine is not available in many
countries, including Britain and Australia.
Although colchicine has been used widely and for a
long time, much remains to be learned about it. Its tox-
ic effects are poorly understood, as is its metabolism,
particularly the mechanisms whereby drugs such as ci-
metidine and erythromycin reduce its metabolism and
increase its plasma and tissue concentrations and hence
its toxic effects.
 
16
 
Nonsteroidal Antiinﬂammatory Drugs
 
Most potent nonsteroidal antiinﬂammatory drugs
are rapidly effective in relieving pain and reducing in-
ﬂammation in patients with acute gout (Table 2), par-
ticularly if the drugs are taken soon after the onset of
the attack.
 
40
 
 Indomethacin, the ﬁrst of these drugs to
be used extensively, provides some pain relief within
two to four hours. Depending on the severity of the at-
tack and its duration, the appropriate dose ranges
from 150 to 300 mg per day, given in divided doses,
with a gradual reduction during a period of ﬁve to sev-
en days as the attack subsides.
 
41
 
 Most other nonsteroi-
dal antiinﬂammatory drugs are effective but no better
than indomethacin,
 
42-45
 
 although few comparative data
are available.
 
40,46
 
 The usefulness of nonsteroidal antiin-
ﬂammatory drugs is limited by their side effects, but in
general, the risks are greatest in elderly patients, par-
ticularly those with renal dysfunction.
 
17-21
 
Corticosteroids
 
Intraarticular injections of a corticosteroid are usual-
ly very effective in patients with acute monarticular
gout,
 
10
 
 and their use is becoming more widespread as
experience with the diagnostic aspiration of joints in-
creases (Table 2). Indeed, aspiration alone can some-
times greatly reduce the pain of gout. The appropriate
dose of corticosteroids is related to the size of the joint;
an intraarticular dose of methylprednisolone acetate
ranges from 5 to 10 mg for a small joint to 20 to 60 mg
for a large joint such as the knee, depending on the vol-
ume of the effusion.
Systemic corticosteroid therapy is usually adminis-
tered only when nonsteroidal antiinﬂammatory drugs
and colchicine have been ineffective or are contraindi-
cated. There are reports of good responses, without a
rebound effect, to oral prednisone (30 to 50 mg per day
initially, with the dose tapered during a period of 7 to
10 days), intramuscular corticotropin (40 U) or triam-
cinolone acetonide (60 mg), or intravenous methylpred-
nisolone (a daily dose of 50 to 150 mg administered
during a 30-minute period, with the dose tapered dur-
ing a period of 5 days).
 
11-13
 
P
 
ROPHYLAXIS
 
 
 
AGAINST
 
 A
 
CUTE
 
 G
 
OUT
 
Acute attacks of gout may be prevented by small dos-
es of either colchicine or nonsteroidal antiinﬂammatory
drugs (Table 2). Prophylactic therapy should be admin-
istered before the initiation of measures to correct the
hyperuricemia. Prophylaxis with colchicine clearly di-
minishes the rate of recurrent acute attacks, whether or
not the serum urate concentration is normal.
 
22,23
 
 In one
study of 540 patients, colchicine was totally effective in
82 percent of the patients, satisfactory in 12 percent,
and ineffective in only 6 percent. Colchicine reduces
the number of inﬂammatory cells in synovial ﬂuid in
patients with gout who are asymptomatic, suggesting
that the drug interferes with the chemotactic response
and reduces subclinical joint inﬂammation.
 
24
 
 Although
the necessary duration of prophylaxis has not been es-
tablished, continuation of therapy for at least a year af-
ter the serum urate concentration has returned to a
normal level is usually sufﬁcient. A myoneuropathy has
occasionally been reported during prophylaxis with col-
chicine in patients with a creatinine clearance of 50 ml
per minute or less.
 
47-50
 
Nonsteroidal antiinﬂammatory drugs are also useful
for prophylactic therapy. No controlled comparison be-
tween such drugs and colchicine has been undertak-
en,
 
25
 
 but colchicine probably has less serious toxic ef-
fects. Prophylaxis with colchicine is therefore preferable,
with a nonsteroidal antiinﬂammatory drug added if col-
chicine proves inadequate.
 
C
 
ORRECTION
 
 
 
OF
 
 H
 
YPERURICEMIA
 
Gout can be prevented by identifying and correcting
the cause of hyperuricemia or by administering drugs
that inhibit the synthesis of urate or increase its excre-
tion. Many factors affect the serum urate concentration
(Table 3), including conditions that lead to increased
degradation of ATP to AMP, which is not reused but
degraded to adenosine and inosine and thence to the
purine bases and urate.
 
51
 
 By this mechanism, the inges-
tion of fructose or alcohol, sustained exercise, and tis-
sue hypoxia from any cause can result in the overpro-
duction of urate. A sustained overproduction of urate
also results either from an enzyme mutation or from ex-
cessive cell turnover such as that which occurs in pa-
tients with myeloproliferative disorders and some can-
cers. Another cause of increased urate production is a
high intake of purine (Table 4). Alcohol consumption
 
*To convert values for serum urate to micromoles per liter,
multiply by 59.48.
 
Table 1. Annual Incidence of Gouty Arthritis
According to the Serum Urate 
Concentration.
 
S
 
ERUM
 
 U
 
RATE
 
C
 
ONCENTRATION
 
(mg/dl)*
A
 
NNUAL
 
I
 
NCIDENCE
 
 
 
OF
 
G
 
OUT
 
 (%)
 

 
7.0 0.1–0.5
7.0–8.9 0.5–1.2
 

 
9.0 4.9–5.7
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and obesity are associated not only with an increase in
the production of urate but also with a decrease in its
excretion.
 
51-56
 
 Beer also contains purines, such as guan-
osine, that are degraded to urate.
 
57
 
Thus, potentially reversible factors that contribute to
increased urate production include a high-purine diet,
obesity, and regular alcohol consumption. None of these
factors may be the sole cause of hyperuricemia, but
each may exacerbate it in patients with other causative
factors, such as a decreased capacity for urinary excre-
tion of urate. The purine content of the diet (Table 4)
does not usually contribute more than 1.0 mg per deci-
liter (60 
 
m
 
mol per liter) to the serum urate concentra-
tion, but moderation in dietary purine consumption
(rather than a constant low-purine diet) is nevertheless
indicated in patients who habitually eat large amounts
of food containing purines, either of animal or of vege-
table origin.
Decreased urinary excretion of urate often contrib-
utes to hyperuricemia.
 
58
 
 The problem can be recog-
nized on the basis of a decrease in the 24-hour urinary
excretion of urate (
 

 
330 mg per day [approximately
2 mmol per day]) while the patient is on a low-purine
diet or a low renal clearance or fractional excretion of
urate. In normal persons, urate clearance ranges from
4 to 14 ml per minute
 
59
 
; persons with a low clearance
have greater difﬁculty excreting a urate load than those
with a normal clearance. The clearance of urate is de-
termined in part by genetic factors.
 
60
 
 An important ac-
quired cause of low clearance is intrinsic renal dis-
ease.
 
61
 
 Many drugs also reduce the renal excretion of
urate, especially thiazides and loop diuretics, which
tend to cause a contraction of the plasma volume.
 
5,62
 
Other drugs that decrease urate excretion include low-
dose salicylate, pyrazinamide, ethambutol, and nia-
cin.
 
58
 
 Certain metabolites and hormones, including lac-
tic acid, ketone bodies, angiotensin, and vasopressin,
also reduce urate excretion. In addition, hypertension
can reduce the excretion of urate.
Because the need for a drug that lowers serum urate
concentrations is likely to be lifelong, it is important to
identify the factors contributing to hyperuricemia that
 
*NSAIDs denotes nonsteroidal antiinﬂammatory drugs.
 
Table 2. Drugs Used in the Management of Gout.
 
D
 
RUG
 
* C
 
OMMENT
 
S
 
OURCE
 
To treat acute gouty arthritis
 
Colchicine Inhibits crystal phagocytosis; no effect on urate metabolism; wide 
tissue distribution and binding; persists in leukocytes for 10 
days; excreted in bile, intestinal secretions (enterohepatic 
circulation), and urine 
Increased toxicity in patients who have renal or hepatic dysfunction 
or are receiving concomitant therapy with P-450 enzyme inhib-
itors such as cimetidine, erythromycin, and tolbutamide
Spilberg et al.
 
14
 
 and Roberge et al.
 
15
 
Caraco et al.
 
16
 
 
NSAIDs Effective but use limited by side effects (gastropathy, nitrogen reten-
tion and reduced creatinine clearance, hyperkalemia, abnormal 
liver-function values, and headache); greater risk of side
effects in patients with renal dysfunction
Grifﬁn et al.,
 
17
 
 Hawkey,
 
18
 
 Roth,
 
19
 
 Find-
ling et al.,
 
20
 
 and Unsworth et al.
 
21
 
 
Corticosteroids Effective either by intraarticular (single joint) or systemic route 
(intramuscular, intravenous, or oral); potential for rebound 
inﬂammation and side effects
Gray et al.,
 
10
 
 Axelrod and Preston,
 
11
 
Alloway et al.,
 
12
 
 and Groff et al.
 
13
 
 
 
To prevent acute attacks
 
Colchicine Effective in an oral dose (0.5–1.0 mg per day) adjusted so as not to 
cause diarrhea
Yü and Gutman,
 
22
 
 Yu,
 
23
 
 and Pascual
and Castellano
 
24
 
 
NSAIDs Useful if colchicine alone is insufﬁcient and acute attacks recur fre-
quently; usual dose is 150 to 300 mg of indomethacin per day 
or its equivalent
Kot et al.
 
25
 
 
 
To lower serum urate 
concentrations
 
Probenecid Increases urate excretion; reversed by salicylate; 90% bound to plas-
ma protein; interferes with excretion of many drugs; serious
toxic effects rare, although nausea and rash reported in up 
to 10% of patients; risk of urolithiasis
Bishop et al.
 
26
 
 and Dayton and Perel
 
27
 
 
Sulﬁnpyrazone More potent uricosuric agent than probenecid (wt/wt); also reduces 
platelet aggregation; 98% bound to protein; short half-life, with
uricosuric metabolites; renal excretion and uricosuria inhibited 
by salicylate; risk of urolithiasis
Dieterle et al.,
 
28
 
 Lecaillon et al.,
 
29
 
 Wil-
cox et al.,
 
30
 
 and Kovalchik
 
31
 
 
Salicylate Reduces urate excretion in low doses; uricosuric in high doses (e.g., 
1 g of aspirin, with 1 g of sodium bicarbonate ﬁve times a 
day); clinically impractical for long-term use
Yü and Gutman
 
32
 
 
Diﬂunisal Fluorinated salicylate with both analgesic and uricosuric properties Emmerson et al.
 
33
 
 
Benzbromarone Potent long-acting uricosuric drug; limited international availability Sorenson and Levinson
 
34
 
 
Allopurinol Only xanthine oxidase inhibitor available; rapidly metabolized to 
oxypurinol, an analogue of xanthine that also inhibits xanthine ox-
idase; longer half-life of oxypurinol (14–28 hr) makes one daily 
dose possible; excretion of oxypurinol impaired in patients with 
renal insufﬁciency but increased by uricosuric drugs
Rundles et al.,
 
35
 
 Spector,
 
36
 
 and Hande
et al.
 
37
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may be correctable. The history and physical examina-
tion will reveal many of these factors, and a simple se-
ries of investigations can provide evidence of intrinsic
overproduction or underexcretion of uric acid. Urate
excretion should be determined by measuring serum
urate and creatinine concentration and 24-hour urinary
excretion of urate and creatinine before and after the
dietary restriction of purines and alcohol for one week.
 
63
 
The results (Table 5) allow an estimation of the renal
handling of urate, calculated as either the clearance or
the fractional excretion of urate ([urate clearance 
 

 
creatinine clearance] 
 

 
100 percent), as well as an esti-
mation of glomerular function (creatinine clearance),
basal urate production (as indicated by the 24-hour ex-
cretion of urate during the low-purine diet), dietary con-
tribution (including alcohol) as reﬂected by the fall in
the serum and 24-hour urinary urate values during the
low-purine diet, and the usual volume of urine (
 

 
1 ml
per minute is desirable
 
64
 
).
If dietary and lifestyle factors are identiﬁed and ap-
propriate changes made, the serum urate concentration
may fall substantially. However, many patients will
need medication to control the hyperuricemia.
Gout may be prevented by reducing serum urate con-
centrations to values less than 6.0 mg per deciliter (360
 
m
 
mol per liter). A reduction to less than 5.0 mg per dec-
iliter (300 
 
m
 
mol per liter) may be required for the re-
sorption of tophi. Therapy with a drug that lowers se-
rum urate concentrations should be considered when
all the following criteria are met: the cause of the hy-
peruricemia cannot be corrected or, if corrected, does
not lower the serum urate concentration to less than 7.0
mg per deciliter (420 
 
m
 
mol per liter); the patient has
had two or three deﬁnite attacks of gout or has tophi;
and the patient is convinced of the need to take medi-
cation regularly and permanently.
Two classes of drugs are available: uricosuric drugs
and xanthine oxidase inhibitors (Table 2). Uricosuric
drugs increase the urinary excretion of urate, thereby
lowering the serum urate concentration. The main risk
associated with these drugs involves the increase in the
urinary excretion of urate that occurs soon after the ini-
tiation of therapy. In contrast, xanthine oxidase inhibi-
tors block the ﬁnal step in urate synthesis, reducing the
production of urate while increasing that of its precur-
sors, xanthine and hypoxanthine (the oxypurines). In
general, a xanthine oxidase inhibitor is indicated in pa-
tients with increased urate production, and a uricosuric
drug in those with low urate clearance. Many patients,
however, have both factors — for example, a patient
with a low urate clearance and a high dietary intake of
purines and alcohol. Nonetheless, allopurinol is effective
in lowering serum urate concentrations in patients with
overproduction or underexcretion of urate or both. The
main side effect is hypersensitivity, and a severe sensitiv-
ity reaction to allopurinol dictates the choice of a urico-
suric drug. Uricosuric drugs are hazardous if the urinary
urate concentration is high (as it is in urate overproduc-
tion) and are contraindicated if the ﬂow of urine is sub-
optimal (consistently 
 

 
1 ml per minute
 
64
 
) or if the pa-
tient has a history of renal calculi or inadequate renal
function (creatinine clearance 
 

 
50 ml per minute). Al-
though there is controversy about the relative merits of
these two classes of drugs, there are advantages in being
able to choose the more appropriate type for an individ-
ual patient.
A potential complication of these drugs is the precip-
itation of acute attacks of gout. The mechanism is poor-
ly understood, but it is usually attributed to the sudden
change in the serum urate concentration. The risk can
be minimized by concurrently administering prophylac-
tic drugs, delaying urate-lowering therapy until several
weeks after the last attack of gout, and commencing
therapy with a low dose of the drug that is chosen.
 
Uricosuric Drugs
 
The greatest potential risks of therapy with uricosuric
drugs are the formation of uric acid crystals in urine and
the deposition of uric acid in the renal tubules, pelvis, or
 
*With the exception of intrinsic renal disease, these causes of reduced urate excretion are
potentially reversible.
 
Table 3. Causes of Sustained Hyperuricemia.
 
I
 
NCREASED
 
 U
 
RATE
 
 P
 
RODUCTION
 
R
 
EDUCED
 
 U
 
RATE
 
 E
 
XCRETION
 
Genetic causes Genetic causes
 
Enzyme mutations (e.g., hypoxan-
thine–guanine phosphoribosyl-
transferase deﬁciency)
Reduced clearance or fractional excre-
tion of urate
 
Acquired causes Acquired causes
 
*
Myeloproliferative disorders Intrinsic renal disease
High purine intake
Obesity and hypertriglyceridemia
Drugs (e.g., thiazide diuretics and low-
dose salicylate)
Alcohol consumption
Fructose consumption
Metabolites (lactate, ketones, angioten-
sin, and vasopressin)
Exercise Renal cause (plasma-volume contrac-
tion, hypertension, reduced urine 
ﬂow [
 

 
1 ml/min], or obesity)
 
*The purine content of a food reﬂects its nucleoprotein content and
turnover. Foods containing many nuclei (e.g., liver) have many purines, as
do rapidly growing foods such as asparagus. The consumption of large
amounts of a food containing a small concentration of purines may pro-
vide a greater purine load than consumption of a small amount of a food
containing a large concentration of purines.
 
Table 4. The Purine Content of Foods.
 
*
 
Low-purine foods
 
Reﬁned cereals and cereal products, cornﬂakes, white bread,
pasta, ﬂour, arrowroot, sago, tapioca, cakes
Milk, milk products, and eggs
Sugar, sweets, and gelatin
Butter, polyunsaturated margarine, and all other fats
Fruit, nuts, and peanut butter
Lettuce, tomatoes, and green vegetables (except those listed
below)
Cream soups made with low-purine vegetables but without 
meat or meat stock
Water, fruit juice, cordials, and carbonated drinks
 
High-purine foods
 
All meats, including organ meats, and seafood
Meat extracts and gravies
Yeast and yeast extracts, beer, and other alcoholic beverages
Beans, peas, lentils, oatmeal, spinach, asparagus, cauliﬂower,
and mushrooms
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ureter, causing renal colic or the de-
terioration of renal function. These
risks can be reduced by initiating
therapy with a low dose and increas-
ing the dose slowly (which also reduc-
es the risk of precipitating acute gout)
and by maintaining a high urine
volume (preferably of alkaline urine,
which can be achieved with 1 g of
sodium bicarbonate taken three to
four times per day), especially during
the early weeks of therapy. Once the
serum urate concentration has de-
clined, the increment in urinary urate
excretion due to the uricosuric drug
is relatively small in comparison with
the usual daily variations. Since the
risks associated with crystalluria oc-
cur each time therapy with a uricosu-
ric drug is started, compliance is particularly important.
The most commonly used uricosuric drugs are pro-
benecid
 
26,27
 
 and sulﬁnpyrazone.
 
28-31
 
 Satisfactory control
of hyperuricemia (serum urate concentrations less than
6.0 mg per deciliter) can be achieved in 60 percent of
patients with a dose of 1 g of probenecid per day and
in 85 percent of patients with a dose of 2 g per day. In
practice, however, the long-term control of hyperurice-
mia is not adequate in up to 25 percent of patients, for
one reason or another. The uricosuric effect of pro-
benecid is reduced as glomerular function declines, and
the drug has little effect in patients with a creatinine
clearance of less than 50 to 60 ml per minute.
Sulﬁnpyrazone is three to six times more potent than
probenecid on a weight-for-weight basis (Table 2). The
initial dose should be 50 or 100 mg twice daily, with
gradual increments to 200 or even 400 mg twice daily.
The drug is less effective if the patient has renal disease
but may nevertheless normalize the serum urate con-
centration. The uricosuric potency of sulﬁnpyrazone is
its chief problem, however, because of the increased
risk of uric acid crystalluria, and renal failure reversed
by an alkaline diuresis has been reported during treat-
ment with the drug.
 
30,31,65
 
Xanthine Oxidase Inhibition
 
Allopurinol, a pyrazolopyrimidine and an analogue
of hypoxanthine, is the only inhibitor of xanthine oxi-
dase in clinical use (Table 2). In the presence of nor-
mal activity of hypoxanthine–guanine phosphoribosyl-
transferase, purine biosynthesis is inhibited and the
reuse of hypoxanthine to form purine nucleotides is in-
creased.
 
35,36
 
 A dose of 300 mg of allopurinol per day re-
duces serum urate concentrations to normal values in
85 percent of patients with gout, and in some patients
a dose of 100 to 200 mg per day is adequate.
 
66
 
 The risk
of precipitating acute gout is reduced if therapy is be-
gun with a low dose (50 to 100 mg per day) that is in-
creased during a period of three to four weeks. Since
the serum concentration of oxypurinol is related to re-
nal function, the dose of allopurinol should be reduced
in proportion to the glomerular ﬁltration rate, as as-
sessed on the basis of the creatinine clearance.
 
67
 
 The
appropriate dose is 100 mg per day in a patient with a
glomerular ﬁltration rate of approximately 30 ml per
minute, 200 mg per day in a patient with a ﬁltration
rate of approximately 60 ml per minute, and 300 mg
per day in a patient with normal renal function.
Since azathioprine and mercaptopurine are normal-
ly inactivated by xanthine oxidase, inhibition of this en-
zyme by allopurinol increases the toxic effect of the
other two drugs.
 
68,69
 
 To compensate for this effect, the
doses of these drugs should be reduced to about 25 per-
cent of the usual dose in patients receiving allopuri-
nol.
 
68,69
 
A rash develops in approximately 2 percent of pa-
tients treated with allopurinol
 
70
 
 and in approximately
20 percent of those receiving both allopurinol and ampi-
cillin. The rash usually subsides after the allopurinol
has been discontinued and may not recur if therapy is
resumed with a lower dose. The most serious side effect
of allopurinol, which occurs in less than 1 in 1000 cases,
is exfoliative dermatitis, often with vasculitis, fever, liv-
er dysfunction, eosinophilia, and acute interstitial ne-
phritis. Up to 20 percent of patients with this type of
reaction become very sick, and it is more likely to occur
in patients with renal disease or those receiving diuretic
therapy.
 
71,72
 
 Prednisone seems to be effective in such
patients,
 
73 
 
but the discontinuation of allopurinol and
the use of supportive therapy may be sufﬁcient in cases
that are not severe.
Desensitization by either the oral or intravenous
route has been successful in some patients with minor
hypersensitivity rashes but has rarely been successful in
those with more serious side effects.
 
74,75
 
 In some pa-
tients with hypersensitivity, lymphocytes react to oxy-
purinol but not to allopurinol, which suggests that the
metabolite may be the causative agent.
 
76
 
 The success of
 
*Adapted from Emmerson
 
63
 
 with the permission of the publisher.
†During and after the low-purine diet.
‡To convert values for urinary urate excretion to millimoles per day, multiply by 0.005948.
§To convert values for serum urate to micromoles per liter, multiply by 59.48.
 
Table 5. Urate and Creatinine Values before, during, and after Dietary Restriction of
Purines, According to the Cause of Hyperuricemia.*
CAUSE OF
HYPERURICEMIA
CREATININE
CLEARANCE
URATE
CLEARANCE
URINARY URATE
EXCRETION
FALL IN
SERUM URATE†
FALL IN
URINARY URATE
EXCRETION†
High purine consumption Normal Normal Normal Increased Increased
Primary urate underexcre-
tion with normal renal 
function
Normal Greatly
reduced
Greatly
reduced 
Normal or
increased
Normal
Renal disease (primary or 
secondary)
Greatly
reduced
Greatly
reduced
Greatly
reduced
Increased Increased
Endogenous urate overpro-
duction
Normal Normal or
increased
Greatly
increased
Normal or
reduced
Normal or
reduced
Normal range 100–130
ml/min
4–14
ml/min
330–600 mg/day‡ 1.0 mg/dl§ 200 mg/day‡
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desensitization is unpredictable, and it may be hazard-
ous in patients who have had a severe reaction.77
Allopurinol is indicated principally for patients with
established gout, particularly those who also have uroli-
thiasis, because the drug has a prophylactic effect in
both uric acid and calcium oxalate nephrolithiasis.78,79
Such prophylaxis may be particularly useful in patients
with renal disease, many of whom have a poor response
to uricosuric drugs. Allopurinol is also indicated in pa-
tients with secondary gout and in those with myelopro-
liferative disorders and excessive cell turnover.80,81
Goals of Urate-Lowering Therapy
The aim of urate-lowering therapy is to reduce the
serum urate concentrations to about 6.0 mg per deci-
liter and preferably even lower if the patient has either
clinical or radiographic evidence of tophi.82 Once the
serum urate concentration has declined, the patient
should be evaluated periodically, with the frequency of
monitoring depending on whether the serum urate con-
centration remains low and whether the patient has
cardiovascular risk factors, such as hypertension or hy-
perlipidemia, or renal insufﬁciency — conditions that
are frequently present in patients with gout.
The need for permanent drug treatment in patients
with gout has recently been questioned. Intermittent
therapy or the withdrawal of drugs that lower serum
urate concentrations leads to a recurrence of acute gout
and tophi; the acute attacks often recur within six
months, and the tophi within three years.83,84 Therefore,
urate-lowering drug treatment should be lifelong.
CHRONIC COMPLICATED AND UNRESPONSIVE GOUT
Problems in the management of gout are usually due
to the failure to prescribe prophylactic colchicine dur-
ing the early period of treatment when hyperuricemia
ﬂuctuates, the initiation of therapy to lower serum urate
concentrations while the patient still has gouty inﬂam-
mation, or poor compliance.
Hyperuricemia persists in some patients despite ap-
parently adequate compliance with the regimen of med-
ication. This lack of response may be due to the persist-
ence of factors promoting hyperuricemia, particularly
regular alcohol consumption, diuretic therapy, and obe-
sity. Dependency on diuretics can often be corrected by
the addition of an angiotensin-converting–enzyme in-
hibitor.85 In the absence of such treatable factors, allo-
purinol and a uricosuric drug may both be required. Al-
though the uricosuric drug will reduce the effectiveness
of the allopurinol by promoting the elimination of oxy-
purinol, it will provide a uricosuric effect.
The most difﬁcult clinical problem arises when a pa-
tient who has tophaceous gout with renal disease be-
comes sensitive to allopurinol and the sensitivity cannot
be corrected. The renal disease is usually mild to mod-
erate in severity and in many cases contributes to the
development of sensitivity to allopurinol. Such patients
should be treated with a maximal dose of a potent uri-
cosuric drug such as sulﬁnpyrazone, with diuretic drugs
avoided and more vigorous attention paid to the cor-
rectable factors promoting hyperuricemia. If the serum
urate concentration does not decline appreciably, the
emphasis must be placed on symptomatic therapy rath-
er than corrective therapy.
SUMMARY
We now have sufﬁcient knowledge to be able to iden-
tify the factors contributing to hyperuricemia in most
patients with gout. Some of these factors, such as obe-
sity, a high-purine diet, regular alcohol consumption,
and diuretic therapy, may be correctable. In patients
with persistent hyperuricemia, regular medication should
lower the serum urate concentration to an optimal lev-
el. The continuing challenge is to educate patients about
correctable factors and the importance of regular med-
ication and ensure their compliance so that attacks of
gout do not recur.
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